Kelli Robertson, APRN
Payments from drug & device makers
Across 80 payments — averaging $67.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$594
- Sanofi-aventis U.S. LLC$221
- Lilly USA, LLC$148
- GSK$141
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $1,357 |
| AstraZeneca | 21 | $1,250 |
| Novo Nordisk | 7 | $594 |
| Sanofi-aventis U.S. LLC | 2 | $221 |
| Lilly USA, LLC | 2 | $148 |
| GSK | 3 | $141 |
| Abbott | 1 | $127 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $118 |
| QOL Medical, LLC | 1 | $116 |
| Madrigal Pharmaceuticals | 1 | $112 |
| Neurelis, Inc. | 1 | $101 |
| Idorsia Pharmaceuticals US Inc | 1 | $100 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $100 |
| Merck | 1 | $97 |
| Sanofi | 1 | $97 |
| Ardelyx, Inc. | 1 | $89 |
| Gilead | 1 | $87 |
| Jazz Pharmaceuticals Inc. | 1 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $76 |
| Bayer | 3 | $60 |
| UCB, Inc. | 1 | $28 |
| Itamar Medical Inc | 2 | $27 |
| Boston Scientific | 1 | $23 |
| Novartis | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,375 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 161 | $235,482 |
| OzempicSemaglutide | 121 | $146,722 |
| JardianceEmpagliflozin | 75 | $87,261 |
| EliquisApixaban | 44 | $55,491 |
| FarxigaDapagliflozin Propanediol | 50 | $50,258 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $47,151 |
| LinzessLinaclotide | 57 | $38,851 |
| MyrbetriqMirabegron | 46 | $35,392 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $34,779 |
| JanuviaSitagliptin Phosphate | 28 | $30,889 |
| WegovySemaglutide | 15 | $24,919 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $19,988 |
| VraylarCariprazine Hcl | 13 | $17,791 |
| XareltoRivaroxaban | 15 | $13,759 |
| Repatha SureclickEvolocumab | 17 | $10,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $148 | $235,482161 claims |
| Novo NordiskOzempic, Wegovy | $594 | $171,641136 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,250 | $93,801116 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $19 | $92,78587 claims |
| AbbVieLinzess, Vraylar, Synthroid | $1,357 | $60,223121 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $141 | $54,58586 claims |
| MerckJanuvia | $97 | $30,88928 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $221 | $19,98826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Bush
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.